Consultant Medical Oncologist / Tokyo / Chertsey / London / /
Company
Astellas Pharma Europe Ltd. / Astellas Pharma Europe Astellas Pharma / Astellas Pharma Inc. / Medivation Inc. / Macmillan / New England Journal / /
Continent
Africa / Europe / South America / /
Country
South Africa / United States / Canada / Australia / United Kingdom / /
Event
Business Partnership / /
Facility
Institute of Cancer Research / National Cancer Institute / /
IndustryTerm
treatment of these diseases / treatment of men with advanced prostate cancer / treatment for the management of advanced prostate cancer / medical media / treatment of adult men with mCRPC whose disease / pharmaceutical / prostate cancer treatment / biopharmaceutical / Treatment of advanced prostate cancer / pharmaceuticals / pharmaceutical market / Treatment for advanced prostate cancer / manufacturing plants / /
MedicalCondition
advanced disease / metastatic prostate cancer / common disease / castration-resistant prostate cancer / mCRPC whose disease / metastatic disease / Prostate cancer UK / incurable advanced prostate cancer / Prostate cancer / prostate tumours / serious diseases / advanced prostate cancer / common cancer / cancer / disease / tumour / diseases / metastatic castrationresistant prostate cancer / UK.ii Although early stage disease / /
National Cancer Institute / European Medicines Agency / Institute of Cancer Research / London / and Consultant Medical Oncologist / U.S. Food and Drug Administration / Cancer Drugs Fund / NHS / /
Person
Alan McDougall Katy Gray / Johann de Bono / Astellas Pharma / / /
Position
Director Senior / Account Manager / Medical Director / Professor of Experimental Cancer Medicine / Professor / Global Chief Investigator / /
Product
testosterone / /
PublishedMedium
Cancer Research / New England Journal of Medicine / /
For UK consumer and medical media Embargoed until[removed]Thursday 11th July 2013 New treatment for the management of advanced prostate cancer after failure on first-line hormonal treatments and docetaxel chemotherapy, now